App-Quantinova.ai

Dana E. Rathkopf - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

CB-7598

Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC) A physician survey linked to patient chart reviews in the United States.

Stephen J. Freedland - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Androgen Tear

Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).

Howard M. Sandler - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Bicalutamide

Association between depth of response (DepOR) and clinical outcomes Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

Cristina Suárez - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.

David Cella - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Ipilimumab

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study.

Martin H Voss - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Pembrolizumab

Trial in progress A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy.

Amishi Yogesh Shah - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

Avelumab

[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC A VISION substudy.

Phillip Kuo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

N/A

Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Susan Halabi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Further results from the phase III PROpel trial.

Antoine Thiery-Vuillemin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Prednisolone

Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC) A VISION study subgroup analysis.

Scott T. Tagawa - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Androgen Tear

Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer Pharmacokinetics data from the PROpel trial.

Andrew J. Armstrong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Prednisolone

Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.

Neeraj Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Androgen Tear

Comparative healthcare research outcomes of novel Surgery in prostate cancer (IP4-CHRONOS) Pilot RCT assessing feasibility of randomization for focal therapy in localized prostate cancer.

Deepika Reddy - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Bicalutamide

Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC) Results from Cohorts 3, 4, 5 of the COSMIC-021 study.

Sumanta K. Pal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Atezolizumab

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC) Analysis of progression after first subsequent therapy in KEYNOTE-426.

Thomas Powles - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Pembrolizumab

Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer A systematic review and meta-analysis.

Waleed Ikram - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cisplatin

CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).

Wassim Kassouf - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Durvalumab

Is there a role for surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC)?

Esmail Mutahar Al-Ezzi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC Trial).

Emily Renninson - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Penile carcinoma

Cisplatin

Filters

45280 Abstracts